1 active not recruiting, 1 suspended. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Suspended 1 |
| Phase 2 | 2 | Active not recruiting 1, Suspended 1 |
Follow E7777 fusion protein: new trials by email Literature Review of E7777 fusion protein trials Research Report on E7777 fusion protein
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Pembrolizumab, E7777 - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | Alexander B Olawaiye, MD | 25 | 2022-09-30 | 2026-05-29 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-01-15 |
Carcinoma, Ovarian Epithelial (1) · Lymphoma, Large B-Cell, Diffuse (1) · Turcot syndrome (1)
Alexander B Olawaiye, MD (1) · Masonic Cancer Center, University of Minnesota (1)
United States (2)
Alexander Olawaiye, MD (1) · Veronika Bachanova, MD (1)